\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ the\\ patient\\ is\\ not\\ know\\ to\\ be\\ receiving\\ any\\ treatment\\ at\\ this\\ time\\.\\ \\ this\\ follow\\-up\\ cxr\\ demonstrates\\ progression\\ from\\ stage\\ i\\ to\\ stage\\ ii\\ disease\\.\\ \\ this\\ would\\ be\\ an\\ indication\\ for\\ beginning\\ treatment\\ with\\ corticosteroids\\.\ \(0\)\
\-\ the\\ pa\\ and\\ lat\\ chest\\ radiographs\\ presented\\ here\\ continue\\ to\\ demonstrate\\ significant\\ paratracheal\\ and\\ bilateral\\ perihilar\\ lymph\\ node\\ enlargement\\ as\\ well\\ as\\ subcarinal\\ adenopathy\\.\\ \\ in\\ addition\\,\\ there\\ is\\ a\\ diffuse\\ reticulonodular\\ pattern\\ of\\ parenchymal\\ involvement\\,\\ greater\\ in\\ the\\ upper\\ lung\\ fields\\.\\ \\ these\\ findings\\ are\\ consistent\\ with\\ progression\\ from\\ stage\\ i\\ to\\ stage\\ ii\\ disease\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ sarcoidosis\ \(108\)\
\-\ pneumoconiosis\\ \\(silicosis\\)\ \(0\)\
\-\ infection\\ \\(tb\\,\\ histoplasmosis\\,\\ coccidiodomycosis\\,\\ blastomycosis\\)\ \(0\)\
\-\ malignancy\\ \\(lymphoma\\,\\ metastatic\\ dz\\)\ \(0\)\
\-\ 32\\ yo\\ black\\ female\\ who\\ presented\\ approximately\\ a\\ year\\ ago\\ with\\ a\\ one\\ year\\ history\\ of\\ red\\-brown\\ maculopapular\\ lesions\\ involving\\ the\\ medial\\ portion\\ of\\ her\\ eyelids\\,\\ bilaterally\\.\\ \\ she\\ was\\ otherwise\\ asymptomatic\\.\\ \\ she\\ received\\ a\\ frontal\\ chest\\ radiograph\\ at\\ that\\ time\\ which\\ demonstrated\\ a\\ classic\\ sarcoid\\ 1\\,2\\,3\\ sign\\ of\\ right\\ paratracheal\\ and\\ bilateral\\ perihilar\\ lymph\\ node\\ enlargement\\ without\\ parenchymal\\ involvement\\.\\ \\ for\\ the\\ past\\ year\\,\\ she\\ has\\ been\\ followed\\ by\\ a\\ pulmonologist\\ and\\ is\\ not\\ known\\ to\\ be\\ receiving\\ any\\ treatment\\.\\ \\ her\\ pfts\\ demonstrate\\ a\\ mild\\ restrictive\\ pattern\\.\\ \\ the\\ studies\\ presented\\ here\\ are\\ part\\ of\\ her\\ routine\\ follow\\-up\\.\ \(0\)\
\-\ although\\ sarcoidosis\\ affects\\ males\\ and\\ females\\ of\\ all\\ ages\\ and\\ races\\,\\ it\\ is\\ more\\ prevalent\\ in\\ female\\ adults\\ younger\\ than\\ 40\\ years\\ of\\ age\\ of\\ african\\ american\\ ethnic\\ background\\ \\(lifetime\\ risk\\ of\\ 2\\.4\\ percent\\ for\\ blacks\\ versus\\ 0\\.85\\ percent\\ for\\ whites\\)\\,\\ such\\ as\\ this\\ patient\\.\\ \\ additionally\\,\\ such\\ as\\ with\\ this\\ patient\\,\\ approximately\\ 50\\%\\ of\\ cases\\ are\\ found\\ in\\ patients\\ who\\ are\\ asymptomatic\\ at\\ time\\ of\\ diagnosis\\.\\ \\ as\\ many\\ as\\ 20\\-25\\%\\ of\\ patients\\ have\\ dermatologic\\ manifestations\\,\\ which\\ range\\ from\\ maculopapular\\ lesions\\ affecting\\ the\\ face\\ \\(nares\\,\\ lips\\,\\ eyelids\\)\\ to\\ more\\ characteristic\\ lesions\\ such\\ as\\ lupus\\ pernio\\ \\(red\\/purple\\,\\ indurated\\ plaques\\ and\\ nodules\\ most\\ commonly\\ affecting\\ the\\ nose\\,\\ cheeks\\,\\ ears\\,\\ and\\ lips\\)\\.\\ \\ at\\ presentation\\,\\ this\\ patient\\ had\\ evidence\\ of\\ stage\\ i\\ disease\\,\\ which\\ is\\ defined\\ by\\ presence\\ of\\ hilar\\ adenopathy\\ only\\.\\ \\ patients\\ with\\ stage\\ i\\ disease\\ require\\ no\\ treatment\\ and\\ can\\ be\\ followed\\-up\\ with\\ chest\\ radiographs\\ every\\ six\\ months\\.\\ \\ 55\\-90\\%\\ of\\ patients\\ with\\ stage\\ i\\ disease\\ experience\\ regression\\ of\\ the\\ hilar\\ adenopathy\\.\\ \\ this\\ patient\\ now\\ has\\ evidence\\ of\\ stage\\ ii\\ disease\\,\\ characterized\\ by\\ hilar\\ adenopathy\\ plus\\ interstitial\\ infiltrates\\ \\(typically\\ more\\ predominant\\ in\\ the\\ upper\\ lungs\\)\\.\\ \\ oral\\ corticosteroids\\ used\\ for\\ 6\\-24\\ months\\,\\ although\\ not\\ conclusively\\ shown\\ to\\ improve\\ long\\-term\\ outcomes\\,\\ are\\ typically\\ used\\ in\\ patients\\ with\\ stage\\ ii\\ or\\ iii\\ disease\\,\\ with\\ progression\\ of\\ symptoms\\ or\\ radiographic\\ changes\\.\\ \\ 40\\-60\\%\\ of\\ patients\\ with\\ stage\\ ii\\ disease\\ will\\ experience\\ spontaneous\\ remission\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ stage\\:\\ 0\\.3709089073821836\ \(0\)\
\-\ ii\\:\\ 0\\.18361241129957245\ \(0\)\
\-\ of\\:\\ 0\\.17318016881442447\ \(0\)\
\-\ patients\\:\\ 0\\.1572097781483063\ \(0\)\
\-\ adenopathy\\:\\ 0\\.15671537188168053\ \(0\)\
\-\ disease\\:\\ 0\\.15640809358332441\ \(0\)\
\-\ maculopapular\\:\\ 0\\.1423495485821302\ \(0\)\
\-\ as\\:\\ 0\\.13097903756391263\ \(0\)\
\-\ lips\\:\\ 0\\.1285131698559486\ \(0\)\
\-\ progression\\:\\ 0\\.12812602369511428\ \(0\)\
\-\ hilar\\:\\ 0\\.12812602369511428\ \(0\)\
\-\ eyelids\\:\\ 0\\.1226886660572247\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.11836135459345319\ \(0\)\
\-\ this\\:\\ 0\\.11203081909381857\ \(0\)\
\-\ perihilar\\:\\ 0\\.1098131530204515\ \(0\)\
\-\ paratracheal\\:\\ 0\\.10319190557215396\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.10088809128565165\ \(0\)\
\-\ receiving\\:\\ 0\\.09673644640577284\ \(0\)\
\-\ affecting\\:\\ 0\\.093703684392197\ \(0\)\
\-\ the\\:\\ 0\\.09293628911128667\ \(0\)\
\-\ experience\\:\\ 0\\.09263248040796027\ \(0\)\
\-\ percent\\:\\ 0\\.09212212620043088\ \(0\)\
\-\ with\\:\\ 0\\.09120191785474975\ \(0\)\
\-\ such\\:\\ 0\\.08988045402095106\ \(0\)\
\-\ treatment\\:\\ 0\\.0887467600745445\ \(0\)\
\-\ here\\:\\ 0\\.0887313742301348\ \(0\)\
\-\ are\\:\\ 0\\.0883676467556939\ \(0\)\
\-\ her\\:\\ 0\\.08729440269730508\ \(0\)\
\-\ and\\:\\ 0\\.08661951412320552\ \(0\)\
\-\ parenchymal\\:\\ 0\\.08368015655412918\ \(0\)\
\-\ she\\:\\ 0\\.0831770111619764\ \(0\)\
\-\ time\\:\\ 0\\.08282056982903885\ \(0\)\
\-\ to\\:\\ 0\\.08150761606312405\ \(0\)\
\-\ presented\\:\\ 0\\.0814817115624191\ \(0\)\
\-\ lesions\\:\\ 0\\.08024762795620642\ \(0\)\
\-\ node\\:\\ 0\\.08006621196812652\ \(0\)\
\-\ more\\:\\ 0\\.07672585838486577\ \(0\)\
\-\ patient\\:\\ 0\\.0757444115118065\ \(0\)\
\-\ be\\:\\ 0\\.07557632259496491\ \(0\)\
\-\ pernio\\:\\ 0\\.07448539801521385\ \(0\)\
\-\ chest\\:\\ 0\\.07375575108086387\ \(0\)\
\-\ lymph\\:\\ 0\\.07243613989578221\ \(0\)\
\-\ enlargement\\:\\ 0\\.0714151821219782\ \(0\)\
\-\ coccidiodomycosis\\:\\ 0\\.0711747742910651\ \(0\)\
\-\ races\\:\\ 0\\.0711747742910651\ \(0\)\
\-\ conclusively\\:\\ 0\\.0711747742910651\ \(0\)\
\-\ for\\:\\ 0\\.07058436283527156\ \(0\)\
\-\ at\\:\\ 0\\.07036960078563083\ \(0\)\
\-\ used\\:\\ 0\\.06973711510055129\ \(0\)\
\-\ pattern\\:\\ 0\\.06954686045718929\ \(0\)\
\-\ in\\:\\ 0\\.06951980206771666\ \(0\)\
\-\ ethnic\\:\\ 0\\.06882584937736554\ \(0\)\
\-\ dermatologic\\:\\ 0\\.06882584937736554\ \(0\)\
\-\ 40\\:\\ 0\\.06850871621748705\ \(0\)\
\-\ involvement\\:\\ 0\\.06742155441899399\ \(0\)\
\-\ typically\\:\\ 0\\.06539392888893514\ \(0\)\
\-\ blacks\\:\\ 0\\.0642565849279743\ \(0\)\
\-\ is\\:\\ 0\\.06377597087845477\ \(0\)\
\-\ which\\:\\ 0\\.06353591176290861\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.06341629672629938\ \(0\)\
\-\ although\\:\\ 0\\.06341629672629938\ \(0\)\
\-\ blastomycosis\\:\\ 0\\.06316630073951722\ \(0\)\
\-\ followed\\:\\ 0\\.06290460978347936\ \(0\)\
\-\ pfts\\:\\ 0\\.06220460192906801\ \(0\)\
\-\ lifetime\\:\\ 0\\.06220460192906801\ \(0\)\
\-\ cheeks\\:\\ 0\\.06134433302861235\ \(0\)\
\-\ restrictive\\:\\ 0\\.060566125148074065\ \(0\)\
\-\ whites\\:\\ 0\\.060566125148074065\ \(0\)\
\-\ radiographs\\:\\ 0\\.060417341216846096\ \(0\)\
\-\ any\\:\\ 0\\.06020246962323393\ \(0\)\
\-\ pulmonologist\\:\\ 0\\.05985567701536846\ \(0\)\
\-\ prevalent\\:\\ 0\\.05985567701536846\ \(0\)\
\-\ approximately\\:\\ 0\\.059437946774874593\ \(0\)\
\-\ by\\:\\ 0\\.05933679938103727\ \(0\)\
\-\ indurated\\:\\ 0\\.05920212808681695\ \(0\)\
\-\ subcarinal\\:\\ 0\\.05859703629012598\ \(0\)\
\-\ nares\\:\\ 0\\.05859703629012598\ \(0\)\
\-\ dz\\:\\ 0\\.05803370930446359\ \(0\)\
\-\ reticulonodular\\:\\ 0\\.05701175189760821\ \(0\)\
\-\ plus\\:\\ 0\\.05701175189760821\ \(0\)\
\-\ remission\\:\\ 0\\.05654505329121969\ \(0\)\
\-\ pneumoconiosis\\:\\ 0\\.05568478439076403\ \(0\)\
\-\ outcomes\\:\\ 0\\.05568478439076403\ \(0\)\
\-\ from\\:\\ 0\\.05549421237718319\ \(0\)\
\-\ silicosis\\:\\ 0\\.05528641256597722\ \(0\)\
\-\ not\\:\\ 0\\.0551614642014143\ \(0\)\
\-\ months\\:\\ 0\\.054222171008328025\ \(0\)\
\-\ know\\:\\ 0\\.05419612837752014\ \(0\)\
\-\ regression\\:\\ 0\\.05293748765227766\ \(0\)\
\-\ evidence\\:\\ 0\\.05287338111034065\ \(0\)\
\-\ who\\:\\ 0\\.05269268764286749\ \(0\)\
\-\ background\\:\\ 0\\.052374160666615266\ \(0\)\
\-\ predominant\\:\\ 0\\.052374160666615266\ \(0\)\
\-\ ears\\:\\ 0\\.05210643167297898\ \(0\)\
\-\ indication\\:\\ 0\\.051847203463820594\ \(0\)\
\-\ histoplasmosis\\:\\ 0\\.051847203463820594\ \(0\)\
\-\ beginning\\:\\ 0\\.05135220325975989\ \(0\)\
\-\ infiltrates\\:\\ 0\\.05135220325975989\ \(0\)\
\-\ bilateral\\:\\ 0\\.05006347973977159\ \(0\)\
\-\ upper\\:\\ 0\\.04977914280286779\ \(0\)\
\-\ lat\\:\\ 0\\.048884079108588926\ \(0\)\
\-\ younger\\:\\ 0\\.04870848088374256\ \(0\)\
\-\ lupus\\:\\ 0\\.04853657973967183\ \(0\)\
\-\ demonstrate\\:\\ 0\\.04842729528941046\ \(0\)\
\-\ males\\:\\ 0\\.048041579535611126\ \(0\)\
\-\ black\\:\\ 0\\.04772750224673551\ \(0\)\
\-\ affects\\:\\ 0\\.04772750224673551\ \(0\)\
\-\ manifestations\\:\\ 0\\.04772750224673551\ \(0\)\
\-\ ages\\:\\ 0\\.047574880929222615\ \(0\)\
\-\ nose\\:\\ 0\\.04713342191867707\ \(0\)\
\-\ plaques\\:\\ 0\\.0469914182915466\ \(0\)\
\-\ females\\:\\ 0\\.0468518421960985\ \(0\)\
\-\ fields\\:\\ 0\\.045813619838140494\ \(0\)\
\-\ continue\\:\\ 0\\.04569265462191158\ \(0\)\
\-\ improve\\:\\ 0\\.04522595601552307\ \(0\)\
\-\ every\\:\\ 0\\.045113333502332716\ \(0\)\
\-\ female\\:\\ 0\\.04495027790187891\ \(0\)\
\-\ sarcoid\\:\\ 0\\.04368079456739784\ \(0\)\
\-\ adults\\:\\ 0\\.043495218334767494\ \(0\)\
\-\ year\\:\\ 0\\.043061554096749215\ \(0\)\
\-\ characterized\\:\\ 0\\.04279241891714441\ \(0\)\
\-\ has\\:\\ 0\\.042549253272278376\ \(0\)\
\-\ interstitial\\:\\ 0\\.042223482173271994\ \(0\)\
\-\ african\\:\\ 0\\.042067953608887196\ \(0\)\
\-\ face\\:\\ 0\\.04199128635307617\ \(0\)\
\-\ six\\:\\ 0\\.04184007827706459\ \(0\)\
\-\ part\\:\\ 0\\.04161839037658103\ \(0\)\
\-\ tb\\:\\ 0\\.04147387328082875\ \(0\)\
\-\ versus\\:\\ 0\\.04119229355825018\ \(0\)\
\-\ received\\:\\ 0\\.04052810618812396\ \(0\)\
\-\ spontaneous\\:\\ 0\\.04052810618812396\ \(0\)\
\-\ iii\\:\\ 0\\.04021523255558626\ \(0\)\
\-\ require\\:\\ 0\\.04003310598406326\ \(0\)\
\-\ 32\\:\\ 0\\.03991390674659184\ \(0\)\
\-\ american\\:\\ 0\\.03973830852174548\ \(0\)\
\-\ additionally\\:\\ 0\\.038356513082315885\ \(0\)\
\-\ addition\\:\\ 0\\.03769920407874812\ \(0\)\
\-\ characteristic\\:\\ 0\\.03765421772388075\ \(0\)\
\-\ oral\\:\\ 0\\.037302980656224324\ \(0\)\
\-\ cxr\\:\\ 0\\.037260119650959884\ \(0\)\
\-\ nodules\\:\\ 0\\.03700757366064856\ \(0\)\
\-\ many\\:\\ 0\\.03672248225991449\ \(0\)\
\-\ range\\:\\ 0\\.03614316114033564\ \(0\)\
\-\ shown\\:\\ 0\\.03610596288577592\ \(0\)\
\-\ routine\\:\\ 0\\.036068933331362976\ \(0\)\
\-\ pa\\:\\ 0\\.03574301412198742\ \(0\)\
\-\ malignancy\\:\\ 0\\.034868557550275646\ \(0\)\
\-\ classic\\:\\ 0\\.03483672514054692\ \(0\)\
\-\ radiographic\\:\\ 0\\.034555683917737945\ \(0\)\
\-\ commonly\\:\\ 0\\.03446411283361088\ \(0\)\
\-\ lungs\\:\\ 0\\.03437355734621494\ \(0\)\
\-\ greater\\:\\ 0\\.03431374020869096\ \(0\)\
\-\ studies\\:\\ 0\\.03416608694898482\ \(0\)\
\-\ ago\\:\\ 0\\.034078759883897164\ \(0\)\
\-\ presence\\:\\ 0\\.03346539972928088\ \(0\)\
\-\ portion\\:\\ 0\\.033305818048529154\ \(0\)\
\-\ risk\\:\\ 0\\.03327952172063537\ \(0\)\
\-\ defined\\:\\ 0\\.0332271817801678\ \(0\)\
\-\ otherwise\\:\\ 0\\.03320113709220418\ \(0\)\
\-\ would\\:\\ 0\\.032970399525220184\ \(0\)\
\-\ involving\\:\\ 0\\.032623953501173725\ \(0\)\
\-\ 50\\:\\ 0\\.03252761016799086\ \(0\)\
\-\ or\\:\\ 0\\.03240602407520592\ \(0\)\
\-\ sign\\:\\ 0\\.03224521881491924\ \(0\)\
\-\ presentation\\:\\ 0\\.03206224190828612\ \(0\)\
\-\ now\\:\\ 0\\.031972268515731206\ \(0\)\
\-\ cases\\:\\ 0\\.031327327919820507\ \(0\)\
\-\ bilaterally\\:\\ 0\\.031062933622066177\ \(0\)\
\-\ radiograph\\:\\ 0\\.03033582561262883\ \(0\)\
\-\ medial\\:\\ 0\\.03031753892468602\ \(0\)\
\-\ past\\:\\ 0\\.03031753892468602\ \(0\)\
\-\ known\\:\\ 0\\.030154776005132115\ \(0\)\
\-\ found\\:\\ 0\\.03013688990213414\ \(0\)\
\-\ frontal\\:\\ 0\\.029977654032450122\ \(0\)\
\-\ will\\:\\ 0\\.029977654032450122\ \(0\)\
\-\ age\\:\\ 0\\.0292409659111613\ \(0\)\
\-\ diffuse\\:\\ 0\\.029209008912427326\ \(0\)\
\-\ yo\\:\\ 0\\.029098134232435027\ \(0\)\
\-\ only\\:\\ 0\\.029098134232435027\ \(0\)\
\-\ demonstrated\\:\\ 0\\.02862444653702273\ \(0\)\
\-\ years\\:\\ 0\\.028550554605083937\ \(0\)\
\-\ lung\\:\\ 0\\.02833280829422724\ \(0\)\
\-\ changes\\:\\ 0\\.0281486807417474\ \(0\)\
\-\ infection\\:\\ 0\\.02813468758878777\ \(0\)\
\-\ lymphoma\\:\\ 0\\.027738979278215888\ \(0\)\
\-\ all\\:\\ 0\\.027725670387325464\ \(0\)\
\-\ been\\:\\ 0\\.027135790523778843\ \(0\)\
\-\ significant\\:\\ 0\\.026892040997461748\ \(0\)\
\-\ one\\:\\ 0\\.026667030308301358\ \(0\)\
\-\ mild\\:\\ 0\\.0264026932704378\ \(0\)\
\-\ than\\:\\ 0\\.0264026932704378\ \(0\)\
\-\ these\\:\\ 0\\.026301542596529618\ \(0\)\
\-\ metastatic\\:\\ 0\\.02554468645692097\ \(0\)\
\-\ symptoms\\:\\ 0\\.025483829011803284\ \(0\)\
\-\ consistent\\:\\ 0\\.02525465586734896\ \(0\)\
\-\ without\\:\\ 0\\.024567166182898604\ \(0\)\
\-\ can\\:\\ 0\\.02444168617376865\ \(0\)\
\-\ most\\:\\ 0\\.024239637065333063\ \(0\)\
\-\ diagnosis\\:\\ 0\\.024144744258975375\ \(0\)\
\-\ it\\:\\ 0\\.023841678438732285\ \(0\)\
\-\ demonstrates\\:\\ 0\\.023399349561595225\ \(0\)\
\-\ have\\:\\ 0\\.02326733998443737\ \(0\)\
\-\ had\\:\\ 0\\.02320594869707378\ \(0\)\
\-\ findings\\:\\ 0\\.02298719650953841\ \(0\)\
\-\ well\\:\\ 0\\.022552399768522267\ \(0\)\
\-\ that\\:\\ 0\\.020212300931515558\ \(0\)\
\-\ there\\:\\ 0\\.01853250417080031\ \(0\)\
\-\ an\\:\\ 0\\.017810562103057814\ \(0\)\
\-\ history\\:\\ 0\\.017794784315049696\ \(0\)\
\-\ was\\:\\ 0\\.016232248203624518\ \(0\)\
\-\ right\\:\\ 0\\.015441919713576002\ \(0\)\
\-\ no\\:\\ 0\\.01514603288591169\ \(0\)\
